Protocol Ledger

NCT04042025 · Phase III · ACTIVE NOT RECRUITING

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

Interventional Phase III clinical trial protocol NCT04042025 sponsored by Novartis in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-02-10 Enrollment: 85 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04042025
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)85 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04042025
Protocol FieldVerified Registry Value
NCT IdentifierNCT04042025
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment85 participants (ACTUAL)
Registered Start Date2020-02-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI